Suloctidil HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 527697

CAS#: 54767-71-4

Description: Suloctidil HCl is a peripheral vasodilator.

Chemical Structure

img
Suloctidil HCl
CAS# 54767-71-4
Instruction

Theoretical Analysis

MedKoo Cat#: 527697
Name: Suloctidil HCl
CAS#: 54767-71-4
Chemical Formula: C20H36ClNOS
Exact Mass: 373.22
Molecular Weight: 374.024
Elemental Analysis: C, 64.23; H, 9.70; Cl, 9.48; N, 3.74; O, 4.28; S, 8.57

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Suloctidil HCl

IUPAC/Chemical Name: (1R*,2S*)-2-(Octylamino)-1-(4-propan-2-ylsulfanylphenyl)propan-1-ol hydrochloride

InChi Key: JRJJHIUHSILDOH-ZHXLSBKVSA-N

InChi Code: InChI=1S/C20H35NOS.ClH/c1-5-6-7-8-9-10-15-21-17(4)20(22)18-11-13-19(14-12-18)23-16(2)3;/h11-14,16-17,20-22H,5-10,15H2,1-4H3;1H/t17-,20-;/m0./s1

SMILES Code: C[C@H](NCCCCCCCC)[C@@H](C1=CC=C(SC(C)C)C=C1)O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 374.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Zeng B, Li J, Wang Y, Chen P, Wang X, Cui J, Liu L, Hu X, Cao Q, Xiao Y, Dong J, Sun Y, Zhou Y. In vitro and in vivo effects of suloctidil on growth and biofilm formation of the opportunistic fungus Candida albicans. Oncotarget. 2017 Jul 25;8(41):69972-69982. doi: 10.18632/oncotarget.19542. eCollection 2017 Sep 19. PubMed PMID: 29050256; PubMed Central PMCID: PMC5642531.

2: Butts A, DiDone L, Koselny K, Baxter BK, Chabrier-Rosello Y, Wellington M, Krysan DJ. A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. Eukaryot Cell. 2013 Feb;12(2):278-87. doi: 10.1128/EC.00314-12. Epub 2012 Dec 14. PubMed PMID: 23243064; PubMed Central PMCID: PMC3571299.

3: Robertson L, Ghouri MA, Kovacs F. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev. 2012 Aug 15;(8):CD002071. doi: 10.1002/14651858.CD002071.pub3. Review. PubMed PMID: 22895926.

4: Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, Wiltfang J, Gulbins E. Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J Med Chem. 2008 Jan 24;51(2):219-37. Epub 2007 Nov 21. PubMed PMID: 18027916.

5: Piccioni F, Roman BR, Fischbeck KH, Taylor JP. A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor. Hum Mol Genet. 2004 Feb 15;13(4):437-46. Epub 2004 Jan 6. PubMed PMID: 14709594.

6: Lapathitis G, Kotyk A. Two forms of yeast plasma membrane H(+)-ATPase: comparison of yield and effects of inhibitors. Folia Microbiol (Praha). 2000;45(3):221-3. PubMed PMID: 11271804.

7: Kotyk A, Lapathitis G, Krenková S. Glucose- and K(+)-induced acidification in different yeast species. Folia Microbiol (Praha). 1999;44(3):295-8. PubMed PMID: 10664885.

8: Lapathitis G, Kotyk A. Different sources of acidity in glucose-elicited extracellular acidification in the yeast Saccharomyces cerevisiae. Biochem Mol Biol Int. 1998 Dec;46(5):973-8. PubMed PMID: 9861451.

9: Itil TM, Eralp E, Ahmed I, Kunitz A, Itil KZ. The pharmacological effects of ginkgo biloba, a plant extract, on the brain of dementia patients in comparison with tacrine. Psychopharmacol Bull. 1998;34(3):391-7. PubMed PMID: 9803773.

10: Cimprich P, Slavík J, Kotyk A. Distribution of individual cytoplasmic pH values in a population of the yeast Saccharomyces cerevisiae. FEMS Microbiol Lett. 1995 Aug 1;130(2-3):245-51. PubMed PMID: 7649447.

11: Verry M, Panak E, Cazenave JP. Antiplatelet therapy in the prevention of ischaemic stroke. Nouv Rev Fr Hematol. 1994 Jun;36(3):213-28. Review. PubMed PMID: 7971242.

12: Kotyk A. Dependence of the kinetics of secondary active transports in yeast on H(+)-ATPase acidification. J Membr Biol. 1994 Feb;138(1):29-35. PubMed PMID: 8189429.

13: Chauvet-Monges AM, Faure R, Crevat A. 1H-NMR study of suloctidil-A23187 calcium ionophore interaction. Chem Biol Interact. 1993 Feb;86(2):163-9. PubMed PMID: 8383582.

14: Tkaczewski W, Buczyński A, Dziedziczak-Buczyńska M, Wachowicz B, Kedziora J. [The effect of suloctidil and acetylsalicylic acid on eicosanoid synthesis in human platelets]. Pol Tyg Lek. 1992 Oct 19-26;47(42-43):970-1. Polish. PubMed PMID: 1338656.

15: Kotyk A, Dvoráková M. Are proton symports in yeast directly linked to H(+)-ATPase acidification? Biochim Biophys Acta. 1992 Mar 2;1104(2):293-8. PubMed PMID: 1347702.

16: Barnett HJ. Clinical trials in stroke prevention. Arzneimittelforschung. 1991 Mar;41(3A):340-4. Review. PubMed PMID: 1859505.

17: De Paermentier F, Heuschling P, Knoops B, Janssens De Varebeke P, Pauwels G, Laszlo De Kaszon-Jakabfalva C, Van den Bosch De Aguilar P. Suloctidil increases the rat brain cortex microvascular regeneration after a lesion. Life Sci. 1989;44(1):41-7. PubMed PMID: 2464117.

18: Chung MW, Komorowski RA, Varma RR. Suloctidil-induced hepatotoxicity. Gastroenterology. 1988 Aug;95(2):490-1. PubMed PMID: 2839389.

19: Valenzuela Miranda C, Aller Reyero MA, Arias Pérez J, Alsasua del Valle A, Arias Pérez JL, Rodríguez Sánchez JC, Durán Sacristán H. [Suloctidil decreases the serotonin concentration in the brain stem of rats with a portacaval shunt]. Rev Esp Enferm Apar Dig. 1988 May;73(5 Pt 2):547-52. Spanish. PubMed PMID: 2845525.

20: Imaizumi S, Suzuki J, Kinouchi H, Yoshimoto T. Superior protective effects of phenytoin against hypoxia in a pharmacological screening test. Neurol Res. 1988 Mar;10(1):18-24. PubMed PMID: 2899850.